Healthcare Services Roundup through April 2018

Healthcare Services Roundup through April 2018

It’s been quite a year for healthcare deals in general, with nearly 600 announced transactions in the first four months. That’s 7% more than there were announced in the first four months of 2017. Dollar volume has soared, too. In 2018, $141.8 billion has already been committed to fund the 588 transactions. Thanks to some mega-billion-dollar deals in 2018, the total is 30% greater than the nearly $109 billion spent in the same period of 2017. Collectively, the Services sectors are booming, which isn’t always the case. Services deals made up 63% of all deals in the first four months of 2018, and 57% of the disclosed dollars, now at $81.3 billion. The Technology sectors... Read More »
Fresenius Sells Sound Inpatient Physicians for $2.15 Billion

Fresenius Sells Sound Inpatient Physicians for $2.15 Billion

What began in 2014 as a grand round of acquisitions of physician medical groups became a multi-billion-dollar exit four years later. Fresenius Medical Care (NYSE: FMS), the world’s largest provider of dialysis products and services, took “an important strategic step to sharpen its U.S. Care Coordination profile” and sell its controlling interest in Sound Inpatient Physicians Holdings, LLC for $2.15 billion. The buyers are led by Summit Partners, a Boston-based private equity firm. Back in June 2014, Fresenius acquired Sound Physicians, as it was called, for $600 million. The group was comprised of more than 1,000 physicians in more than 100 hospitals. The acquisition was... Read More »
Deal of the Week: Prelude Fertility/Vivere Health

Deal of the Week: Prelude Fertility/Vivere Health

Two fertility clinics are banking on growth through acquisitions. At least, their investors are. Miami, Florida-based Prelude Fertility last week announced its acquisition of Vivere Health, LLC, a portfolio company of LLR Partners. Franklin, Tennessee-based Vivere operates fertility practices and labs in partnership with fertility specialists in nine U.S. markets. Since its founding in 2010, it has partnered with fertility specialists to promote or establish their practices while removing the burdens of day-to-day management. It also has egg banking services and a mail-order pharmacy. Prelude Fertility is a reproductive science and technology company. It operates fertility treatment... Read More »
Quest Diagnostics Buys a Fresenius Lab

Quest Diagnostics Buys a Fresenius Lab

Deal volume in the Laboratories, MRI & Dialysis sector is up 6% from this time last year. On September 28, two major players in the laboratory space traded hands and began collaborating on a kidney disease project. Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic testing in the United States, announced its purchase of Shiel Medical Laboratory, Inc. from Fresenius Medical Care (NYSE: FMS). Fresenius acquired Shiel Medical Laboratory in October 2013 via its subsidiary Spectra Labs, which is not affected by the divestiture. Founded in 1919, Shiel Medical is one of the oldest continuously operating clinical laboratories in the United States. Its main testing facility is in... Read More »

Fresenius Banks on Dialysis at Home

Fresenius, a global leader in dialysis, brings dialysis into the home with a $2 billion deal. As hospitals and other providers face mounting pressure to deliver high-quality, lower cost services, one company has taken the initiative to become a world-leader in at-home critical care. On August 7, 2017, Fresenius Medical Care (NYSE: FMS) acquired NxStage Medical, Inc. (NASDAQ: NXTM) for $2.0 billion. Fresenius Medical Care will acquire all outstanding shares of NxStage for $30.00 per common share, valuing the deal at approximately $2.0 billion, including $1.24 million of debt. Multiples work out to 5.11x revenue and 7.97x EBITDA. Based in Boston, NxStage Medical develops, manufactures, and... Read More »

Invitae Adds Reproductive Health Diagnostics

Just a month ago, we reported on molecular-diagnostics firm Invitae (NYSE: NVTA), and its interest in the eHealth sector, following the acquisition of two digital health companies. In July, the company set its sights on other laboratory companies and announced two more acquisitions. Invitae also separately announced that it will sell $73.5 million of its stock through a private placement to be led by existing investors with “significant” participation from multiple new investors, all unnamed. Invitae is one of the fastest growing genetic information companies in the United States, whose longer-term strategy is to aggregate most of the world’s genetic tests into a single service with... Read More »